Janssen Pharmaceuticals, Inc.

Alza Corporation

Janssen Biotech, Inc.

Intarcia Therapeutics, Inc.

Kui Liu

Peter A Krulevitch

Michael G Cannamela

Nick Foley

James McLusky

Ian Scrimgeour

Jimmy Mower

Michael A DesJardin

Beth Hill

Catherine Manya Rohloff

Pauline C Zamora

Stan Lam

James E Matsuura

Zengji Li

Carl Mieczkowski

Paula Dennis

Latha Narayanan

Weiguo Dai

A grip accessory for a manual injection device comprises a housing having a generally hollow body for supporting a manual injection device therein. The housing comprises a distal portion comprising a first opening into which a manual injection device can be inserted, a proximal portion comprising a second opening through which a needle of the manual injection device is extendable, the proximal portion comprising a skin contacting surface at a proximal end of the device. An intermediate portion extends between the proximal and distal portions and guide means is provided on an interior surface of the distal portion for guiding a plunger rod of an injection device during delivery of an injection.

Grip accessory for a manual injection device

A grip accessory for a manual injection device comprises a housing comprising a generally hollow body configured to support a manual injection device therein. The housing comprises a distal portion comprising a first opening into which a manual injection device can be inserted, a proximal portion having a second opening through which the needle of the manual injection device extends. The proximal portion comprises a skin contacting surface at a proximal end of the device that can be placed against an injection site. An intermediate portion extends between the proximal and distal portions.

The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations of antibodies and methods of making and using them.

Non-aqueous high concentration reduced viscosity suspension formulations of antibodies

A suspension formulation for therapeutic use includes a non-aqueous, single-phase vehicle exhibiting viscous fluid characteristics and a particle formulation comprising an erythropoietin receptor agonist dispersed in the vehicle.

Stable suspension formulations of erythropoietin receptor agonists

An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 &#x3bc;g/day to maintain and achieve therapeutic blood or plasma levels of the interferon throughout a substantial period of the administration period.

Implantable device for continuous delivery of interferon

Growing community of inventors

Redwood City, CA, United States of America

Kui Liu